Sunao Fujioka, M.S., Pharmacist

Representative director, CEO, Alpha Fusion

From Japan to Global collaboration: Unleashing therapeutic potential of At-211 based therapy

ABSTRACT

Alpha Fusion Inc. (AF) is a clinical-stage startup in Japan specializing in At-211-based drug development, dedicated to unleashing the therapeutic potential of alpha therapy. Currently, AF is concentrating on clinical advancements in its Thyroid and Prostate programs, establishing a robust supply chain (ranging from coordination with cyclotron stakeholders to GMP manufacturing across various regions), and fostering global collaborations with partners involved in At-211 research and development. Looking ahead, AF aims to intensify its efforts in advancing At-211-based programs worldwide, delivering benefits to patients, the healthcare industry, and academia through collaborations.

SPEAKER BIO

Previously worked for McKinsey, J&J, MSD, and bitBiome (CEO, single cell genomics startup in Japan). At MSD, Sunao played a pivotal role in the launch of KEYTRUDA. As the CEO/COO of bitBiome, Sunao secured collaborative research projects with National Cancer Center Hospital East and Fred Hutchinson Cancer Center. Additionally, Sunao spearheaded the Series B funding round, raising $5 million. M.S. in pharmaceutical sciences from University of Tokyo

Return to conference agenda